Strengthening the Board and Management Team with Clinical and Drug Discovery and Development experts, Sonia Quaratino and Chris Stevenson
Our Mission
Decoding pathogenic changes to the ECM to develop transformational therapies that will improve and extend the lives of patients with fibrotic diseases and solid tumours.
A new powerful platform for de-risking drug discovery
We are developing a broad pipeline internal and partnered therapeutic programmes for fibrosis and solid tumours by leveraging the power of our human extracellular matrix (ECM)-based discovery platform. Not only does the ECM provide cells and tissues with structural support, but it also creates a bioactive microenvironment that promotes physiological and pathological processes.
Our best-in-class proprietary ECM platform
Our patient-centric ECM platform is underpinned by an extensive bioarchive, one of the world’s largest ECM databases, and best-in-class, human in vitro 3-D cell culture bioassays. Together, these unique capabilities transform our ability to identify new targets and biomarkers, investigate novel mechanisms of action, and more accurately predict the efficacy of therapeutic candidates.
“Engitix’ unique proprietary ECM platform has immense potential to improve the efficiency of drug discovery and development processes. In my view, this is an essential factor that needs to be addressed as it underlies the future success of the pharmaceutical industry.”
Eduardo Bravo, Chairman
Partnering strategy
We have several discovery and development collaborations with Takeda Pharmaceuticals in advanced fibrotic liver diseases including non-alcoholic steatohepatitis (NASH), and fibrostenotic inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. We also have a collaboration with Dompé farmaceutici to enable identification and engineering of new precision medicines against fibrosis and solid tumours using Dompé’s AI supercomputer structure-based drug design platform.
All chronic diseases involve changes to the ECM. Our first- and best-in-class ECM discovery platform is able to address all fibrotic and solid tumours indications, and we remain open for new partnerships. If interested, please contact us at info@engitix.com.
Operations
Engitix has a 13,000 square feet facility of purpose-designed office and laboratory space that houses the latest state-of-the-art research instruments and tools. Located at the Westworks building in the prestigious new life science cluster at White City Place, London, UK, we provide a stimulating and innovative research environment with excellent networking opportunities.
Our Story
Engitix was created in 2016 to commercialise cutting-edge ECM research at the Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL) and is now a growing biotechnology company with a discovery stage therapeutic portfolio and over 50 employees.
The Pipeline Chapter (2022-present)
2023
2022
HQ expansion to a total of 13,000 ft2
2022
Expanded partnership with Takeda to develop new anti-fibrotic therapies in inflammatory bowel disease (IBD)
2022
$54M Series A Financing to support the development of Engitix internal pipeline in fibrosis and solid tumours
2022
Strategic collaboration and investment agreement with Dompé
The Platform Chapter (2018-22)
2020
New UK HQ – (> 8,000 ft2) within London’s new biotech Hub, White City
2020
Exclusive partnership with Takeda for ECM-related drug target discovery, development and commercialization in liver fibrosis
2019
Partnership signed with Morphic Therapeutic for ECM-related target ID in inflammatory bowel disease
2019
Takeda awarded Engitix a Golden Ticket to establish its presence in LabCentral, Cambridge, MA
2019
UCL Innovation & Enterprise Award – Provost’s Spirit of Enterprise Award
2018
$7 million Seed Round for advancing the first human ECM platform for drug discovery in fibrosis and solid tumours
2018
F1000Prime Recommended – Mazza G et al; Sci Rep, 2017
The Fee-for-service Chapter (2016-2017)
2017
Revenues from third party contracts in fibrosis – the first commercial application of Engitix 3D ECM platform applied to screen pre-clinical and clinical third-party products
2016
Incorporation of Engitix Ltd – 5yrs of research completed at UCL with more than 30 people working on the ECM
